Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Roche Holdings ADR RHHBY

Healthcare
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more

Recent & Breaking News (OTCQX:RHHBY)

FDA Grants Priority Review for Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer

Business Wire September 29, 2017

Roche gains CE label expansion for PD-L1 testing in lung and bladder cancers in markets where TECENTRIQ is approved

PR Newswire September 28, 2017

Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared to Bendamustine Plus Rituxan

Business Wire September 18, 2017

Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration

Business Wire September 8, 2017

FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome

Business Wire August 30, 2017

FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma

Business Wire August 28, 2017

FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors

Business Wire August 24, 2017

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Roche Holding AG

Business Wire August 7, 2017

FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation

Business Wire August 7, 2017

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Roche Holding AG

Business Wire August 4, 2017

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of the August 9, 2017 Deadline in the Class Action Lawsuit Against Mazor Robotics, Ltd.

Business Wire August 3, 2017

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Roche Holding AG. (RHHBY) and Lead Plaintiff Deadline: August 7, 2017

GlobeNewswire August 3, 2017

ROCHE LOSS NOTICE: Rosen Law Firm Reminds Roche Holding AG Investors of Important Deadline in First Filed Class Action – RHHBY

GlobeNewswire August 3, 2017

FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer

Business Wire August 3, 2017

AUGUST 7 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

GlobeNewswire August 2, 2017

6-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm

GlobeNewswire August 1, 2017

DEADLINE ALERT:  Brower Piven Reminds Investors Of Upcoming Deadline And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Roche Holding AG (OTCQX: RHHBY) To Contact The Firm

GlobeNewswire August 1, 2017

Roche to showcase power of connected lab at AACC 2017 Clinical Lab Expo

PR Newswire July 31, 2017

Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine

Business Wire July 26, 2017

Accenture to Transform Diabetic Patient Care Using Data-driven Analytics Platform

Business Wire July 26, 2017